Literature DB >> 34040258

NF1 mutation drives neuronal activity-dependent initiation of optic glioma.

Michelle Monje1,2,3,4,5, David H Gutmann6, Yuan Pan7, Jared D Hysinger7, Tara Barron7, Nicki F Schindler7, Olivia Cobb8, Xiaofan Guo8, Belgin Yalçın7, Corina Anastasaki8, Sara B Mulinyawe7, Anitha Ponnuswami7, Suzanne Scheaffer8, Yu Ma8, Kun-Che Chang9, Xin Xia9, Joseph A Toonen8, James J Lennon7, Erin M Gibson7,10, John R Huguenard7, Linda M Liau11, Jeffrey L Goldberg9.   

Abstract

Neurons have recently emerged as essential cellular constituents of the tumour microenvironment, and their activity has been shown to increase the growth of a diverse number of solid tumours1. Although the role of neurons in tumour progression has previously been demonstrated2, the importance of neuronal activity to tumour initiation is less clear-particularly in the setting of cancer predisposition syndromes. Fifteen per cent of individuals with the neurofibromatosis 1 (NF1) cancer predisposition syndrome (in which tumours arise in close association with nerves) develop low-grade neoplasms of the optic pathway (known as optic pathway gliomas (OPGs)) during early childhood3,4, raising  the possibility that postnatal light-induced activity of the optic nerve drives tumour initiation. Here we use an authenticated mouse model of OPG driven by mutations in the neurofibromatosis 1 tumour suppressor gene (Nf1)5 to demonstrate that stimulation of optic nerve activity increases optic glioma growth, and that decreasing visual experience via light deprivation prevents tumour formation and maintenance. We show that the initiation of Nf1-driven OPGs (Nf1-OPGs) depends on visual experience during a developmental period in which Nf1-mutant mice are susceptible to tumorigenesis. Germline Nf1 mutation in retinal neurons results in aberrantly increased shedding of neuroligin 3 (NLGN3) within the optic nerve in response to retinal neuronal activity. Moreover, genetic Nlgn3 loss or pharmacological inhibition of NLGN3 shedding blocks the formation and progression of Nf1-OPGs. Collectively, our studies establish an obligate role for neuronal activity in the development of some types of brain tumours, elucidate a therapeutic strategy to reduce OPG incidence or mitigate tumour progression, and underscore the role of Nf1mutation-mediated dysregulation of neuronal signalling pathways in mouse models of the NF1 cancer predisposition syndrome.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34040258      PMCID: PMC8346229          DOI: 10.1038/s41586-021-03580-6

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   69.504


  23 in total

1.  Functional restoration of mouse Nf1 nonsense alleles in differentiated cultured neurons.

Authors:  Chan Wu; Sukanya Iyer; Scot A Wolfe; Allan Jacobson
Journal:  J Hum Genet       Date:  2022-08-09       Impact factor: 3.755

2.  Dark Rearing in the Visual Critical Period Causes Structural Changes in Myelinated Axons in the Adult Mouse Visual Pathway.

Authors:  Yasuyuki Osanai; Batpurev Battulga; Reiji Yamazaki; Tom Kouki; Megumi Yatabe; Hiroaki Mizukami; Kenta Kobayashi; Yoshiaki Shinohara; Yumiko Yoshimura; Nobuhiko Ohno
Journal:  Neurochem Res       Date:  2022-08-06       Impact factor: 4.414

Review 3.  Insights and opportunities at the crossroads of cancer and neuroscience.

Authors:  Chenchen Pan; Frank Winkler
Journal:  Nat Cell Biol       Date:  2022-09-12       Impact factor: 28.213

Review 4.  The dark side of synaptic proteins in tumours.

Authors:  Jing Li; Yalan Xu; Hai Zhu; Yin Wang; Peifeng Li; Dong Wang
Journal:  Br J Cancer       Date:  2022-05-27       Impact factor: 9.075

5.  IDH-mutated gliomas promote epileptogenesis through d-2-hydroxyglutarate-dependent mTOR hyperactivation.

Authors:  Armin Mortazavi; Islam Fayed; Muzna Bachani; Tyrone Dowdy; Jahandar Jahanipour; Anas Khan; Jemima Owotade; Stuart Walbridge; Sara K Inati; Joseph Steiner; Jing Wu; Mark Gilbert; Chun Zhang Yang; Mioara Larion; Dragan Maric; Alexander Ksendzovsky; Kareem A Zaghloul
Journal:  Neuro Oncol       Date:  2022-09-01       Impact factor: 13.029

Review 6.  Disconnecting multicellular networks in brain tumours.

Authors:  Varun Venkataramani; Matthias Schneider; Ulrich Herrlinger; Frank Winkler; Frank Anton Giordano; Thomas Kuner; Wolfgang Wick
Journal:  Nat Rev Cancer       Date:  2022-04-29       Impact factor: 69.800

7.  Molecular genetic evaluation of pediatric renovascular hypertension due to renal artery stenosis and abdominal aortic coarctation in neurofibromatosis type 1.

Authors:  Dawn M Coleman; Yu Wang; Min-Lee Yang; Kristina L Hunker; Isabelle Birt; Ingrid L Bergin; Jun Z Li; James C Stanley; Santhi K Ganesh
Journal:  Hum Mol Genet       Date:  2022-02-03       Impact factor: 5.121

Review 8.  Therapeutic avenues for cancer neuroscience: translational frontiers and clinical opportunities.

Authors:  Diana D Shi; Jimmy A Guo; Hannah I Hoffman; Jennifer Su; Mari Mino-Kenudson; Jaimie L Barth; Jason M Schenkel; Jay S Loeffler; Helen A Shih; Theodore S Hong; Jennifer Y Wo; Andrew J Aguirre; Tyler Jacks; Lei Zheng; Patrick Y Wen; Timothy C Wang; William L Hwang
Journal:  Lancet Oncol       Date:  2022-02       Impact factor: 54.433

Review 9.  The interplay of autophagy and oxidative stress in the pathogenesis and therapy of retinal degenerative diseases.

Authors:  Kun-Che Chang; Pei-Feng Liu; Chia-Hsuan Chang; Ying-Cheng Lin; Yen-Ju Chen; Chih-Wen Shu
Journal:  Cell Biosci       Date:  2022-01-03       Impact factor: 7.133

Review 10.  Reimagining pilocytic astrocytomas in the context of pediatric low-grade gliomas.

Authors:  Till Milde; Fausto J Rodriguez; Jill S Barnholtz-Sloan; Nirav Patil; Charles G Eberhart; David H Gutmann
Journal:  Neuro Oncol       Date:  2021-10-01       Impact factor: 13.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.